Volume 81, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


AA-amyloidosis in the setting of chronic visceral leishmaniasis (VL) has been reported in animal models but documentation in humans is unavailable. Here, we report on a Portuguese man who in 1996 was diagnosed with both human immunodeficiency virus (HIV)-infection and VL. Antiretroviral treatment led to sustained suppression of HIV viremia but CD4+ lymphocytes rose from 8 to only 160 cells/mL. Several courses of antimony treatment did not prevent VL relapses. Renal failure developed in 2006 and renal biopsy revealed AA-amyloidosis. The patient had cryoglobulinemia and serum immune complexes containing antibodies directed against seven leishmanial antigens. Antimony plus amphotericin B, followed by oral miltefosine resulted in a sustained VL treatment response with elimination of circulating DNA and CD4+ recovery. The concomitant reduction of serum AA levels and disappearance of circulating leishmanial immune complexes suggests that prolonged VL may lead to AA-amyloidosis in immunocompromised humans.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Oliveira AV, Roque-Barreira MC, Sartori A, Campos-Neto A, Rossi MA, 1985. Mesangial proliferative glomerulonephritis associated with progressive amyloid deposition in hamsters experimentally infected with Leishmania donovani. Am J Pathol 120 : 256–262. [Google Scholar]
  2. Poli A, Abramo F, Mancianti F, Nigro M, Pieri S, Bionda A, 1991. Renal involvement in canine leishmaniasis. A light-microscopic, immunohistochemical and electron-microscopic study. Nephron 57 : 444–452. [Google Scholar]
  3. Croan DG, Morrison DA, Ellis JT, 1997. Evolution of the genus Leishmania revealed by comparison of DNA and RNA polymerase gene sequences. Mol Biochem Parasitol 89 : 149–159. [Google Scholar]
  4. Mary C, Faraut F, Drogoul MP, Xeridat B, Schleinitz N, Cuisenier B, Dumon H, 2006. Reference values for Leishmania infantum parasitemia in different clinical presentations: quantitative polymerase chain reaction for therapeutic monitoring and patient follow-up. Am J Trop Med Hyg 75 : 858–863. [Google Scholar]
  5. Navarro M, Bonet J, Bonal J, Romero R, 2006. Secondary amyloidosis with irreversible acute renal failure caused by visceral leishmaniasis in a patient with AIDS. Nefrologia 26 : 745–746. [Google Scholar]
  6. Alex S, Criado C, Fernandez-Guerrero ML, de Gorgolas M, Petkov V, Garcia Perez A, Egido J, Barat A, Manzarbeitia F, Caramelo C, Ortiz A, 2008. Nephrotic syndrome complicating chronic visceral leishmaniasis: re-emergence in patients with AIDS. Clin Nephrol 70 : 65–68. [Google Scholar]
  7. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN, 2007. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356 : 2361–2371. [Google Scholar]
  8. Osick LA, Lee TP, Pedemonte MB, Jacob L, Chauhan P, Navarro C, Comer GM, 1993. Hepatic amyloidosis in intravenous drug abusers and AIDS patients. J Hepatol 19 : 79–84. [Google Scholar]
  9. Cozzi PJ, Abu-Jawdeh GM, Green RM, Green D, 1992. Amyloidosis in association with human immunodeficiency virus infection. Clin Infect Dis 14 : 189–191. [Google Scholar]
  10. Mery JP, Delahousse M, Nochy D, 1993. Amyloidosis and infection due to human immunodeficiency virus. Clin Infect Dis 16 : 733–734. [Google Scholar]
  11. Chan-Tack KM, Ahuja N, Weinman EJ, Wali RK, Uche A, Greisman LA, Drachenberg C, Hawkins PN, Redfield RR, 2006. Acute renal failure and nephrotic range proteinuria due to amyloidosis in an HIV-infected patient. Am J Med Sci 332 : 364–367. [Google Scholar]
  12. Mira JA, Corzo JE, Rivero A, Macias J, De Leon FL, Torre-Cisneros J, Gomez-Mateos J, Jurado R, Pineda JA, 2004. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg 70 : 298–301. [Google Scholar]
  13. Riera C, Fisa R, Ribera E, Carrio J, Falco V, Gallego M, Moner L, Molina I, Portus M, 2005. Value of culture and nested polymerase chain reaction of blood in the prediction of relapses in patients co-infected with leishmania and human immunodeficiency virus. Am J Trop Med Hyg 73 : 1012–1015. [Google Scholar]
  14. Bourgeois N, Lachaud L, Reynes J, Rouanet I, Mahamat A, Bastien P, 2008. Long-term monitoring of visceral leishmaniasis in patients with AIDS: relapse risk factors, value of polymerase chain reaction, and potential impact on secondary prophylaxis. J Acquir Immune Defic Syndr 48 : 13–19. [Google Scholar]
  15. Buffet P, Deray G, Grogl M, Martinez F, Jacobs C, 1995. Tolerance and pharmacokinetics of antimony in a patient with renal failure. Nephrol Dial Transplant 10 : 1477. [Google Scholar]
  16. Sindermann H, Engel KR, Fischer C, Bommer W, 2004. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 39 : 1520–1523. [Google Scholar]

Data & Media loading...


  • Received : 01 Dec 2008
  • Accepted : 22 Apr 2009

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error